Watch stocks you care about
The single, easiest way to keep track of all the stocks that matter...
Your own personalized stock watchlist!
It's a 100% FREE Motley Fool service...
After days of being stuck in neutral, the stock market finally made a move, but it wasn't one that made investors very happy. Most analysts pointed to weak confidence figures from Europe as a reminder that the sovereign-debt situation on the Continent is far from solved. Nervousness about tomorrow's speech from Ben Bernanke also took its toll, as the Dow Jones Industrials (INDEX: ^DJI ) traded down more than 100 points this morning.
Around 10:45 a.m. EDT, just one Dow component traded higher: Coca-Cola (NYSE: KO ) , by a single penny. News reports that the beverage company got the go-ahead to produce energy drinks in India is a sign of the continuing importance of emerging markets to Coca-Cola's overall growth, even if the energy-drink segment is coming under pressure from regulators and government officials.
Meanwhile, losses were consistent across most sectors. AT&T (NYSE: T ) was off 0.6% even as it announced plans to open its first flagship retail location, choosing Chicago's high-profile Magnificent Mile shopping district for the store. With increasing competition from Verizon as the companies prepare for the coming release of the iPhone 5, AT&T hopes to take a page from Apple (Nasdaq: AAPL ) and duplicate the iPhone-maker's retail success.
Finally, Johnson & Johnson (NYSE: JNJ ) fell 0.7%. The company's Janssen subsidiary announced a deal by with Danish biotech Genmab to gain the global licensing rights to daratumumab, a cancer-fighting antibody in development. Although the upfront license fee of $55 million is relatively small, J&J also agreed to invest $80 million in Genmab shares. The move shows how important it is for big pharma companies like J&J to keep their pipelines full.
Find the winners
When markets fall, you want to be sure the stocks you own will end up on top. Apple has done an excellent job of being a market beater, but can its outperformance continue? Get the latest analysis from our top Fools in the Motley Fool's premium report on Apple.